BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler Sells 3,174 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 3,174 shares of the company’s stock in a transaction that occurred on Monday, June 23rd. The shares were sold at an average price of $261.61, for a total transaction of $830,350.14. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

John Oyler also recently made the following trade(s):

• On Tuesday, June 17th, John Oyler sold 1,460 shares of BeOne Medicines stock. The stock was sold at an average price of $256.49, for a total transaction of $374,475.40.
• On Monday, June 16th, John Oyler sold 3,680 shares of BeOne Medicines stock. The stock was sold at an average price of $266.05, for a total value of $979,064.00.
• On Friday, June 6th, John Oyler sold 5,127 shares of BeOne Medicines stock. The shares were sold at an average price of $252.77, for a total value of $1,295,951.79.

BeOne Medicines Price Performance

ONC stock opened at $267.13 on Thursday. The company has a quick ratio of 1.71, a current ratio of 1.96 and a debt-to-equity ratio of 0.05. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $141.31 and a 1-year high of $287.88. The business has a 50 day simple moving average of $247.22. The company has a market cap of $29.28 billion, a P/E ratio of -71.81 and a beta of 0.30.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $1.93. The firm had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.12 billion. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. Sell-side analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ONC shares. TD Securities reaffirmed a “buy” rating and issued a $334.00 price objective on shares of BeOne Medicines in a research note on Thursday, April 24th. JPMorgan Chase & Co. increased their target price on shares of BeOne Medicines from $311.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, April 21st. Wall Street Zen raised shares of BeOne Medicines from a “hold” rating to a “buy” rating in a report on Thursday, May 22nd. Royal Bank Of Canada reduced their price objective on shares of BeOne Medicines from $312.00 to $311.00 and set an “outperform” rating for the company in a research note on Thursday, May 8th. Finally, JMP Securities set a $348.00 price objective on shares of BeOne Medicines in a research report on Friday, February 28th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $319.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.